A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Pauly, Diana ^a   Nagel, Benedikt M ^a   Reinders, Jörg ^a   Killian, Tobias ^a   Wulf, Matthias ^a   Ackermann, Susanne ^b   Ehrenstein, Boris ^c   Zipfel, Peter F ^b,d   Skerka, Christine ^b   Weber, Bernhard H F ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b HANS KNÖLL INSTITUTE   (Germany)

^c Asklepios Klinikum Bad Abbach   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BA ANTIBODY; CLUSTERIN; ECULIZUMAB; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1340; PROPERDIN; PROPERDIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BLOOD SAMPLING; COMPLEMENT ALTERNATIVE PATHWAY; COMPUTER MODEL; CONTROLLED STUDY; CYTOLYSIS; DIAGNOSTIC TEST; DILUTION; DISEASE COURSE; DRUG MECHANISM; DRUG SYNTHESIS; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOREGULATION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROPERDIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REFERENCE VALUE; REPRODUCIBILITY; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATIC DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; COMPLEMENT PATHWAY, ALTERNATIVE; COMPUTER SIMULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNITY, INNATE; MICE; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR; PROPERDIN; REPRODUCIBILITY OF RESULTS;

EID: 84900451435     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096371     Document Type: Article

References (84)

1. Zipfel PF, Heinen S, Józsi M, Skerka C (2006) Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol 43: 97-106. Available: http://www.ncbi.nlm.nih.gov/pubmed/ 16026839. Accessed 2012 Jun 3.
2. Chen Q, Müller D, Rudolph B, Hartmann A, Kuwertz-Bröking E, et al. (2011) Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med 365: 2340-2342. Available: http://www.ncbi.nlm.nih.gov/pubmed/22168663. Accessed 2014 Jan 13.
3. Chen M, Daha MR, Kallenberg CGM (2010) The complement system in systemic autoimmune disease. J Autoimmun 34: J276-86. Available: http://www.ncbi.nlm.nih. gov/pubmed/20005073. Accessed 2013 Nov 8.
4. Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, et al. (2013) Seven new loci associated with age-related macular degeneration. Nat Genet 45: 433-439. Available: http://www.ncbi.nlm.nih.gov/pubmed/23455636. Accessed 2013 Apr 18.
5. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, et al. (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108: 1267-1279. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 1895874&tool=pmcentrez&rendertype=abstract. Accessed 2013 Dec 16.
6. Zipfel PF, Lauer N, Skerka C (2010) The role of complement in AMD. Adv Exp Med Biol 703: 9-24. Available: http://www.ncbi.nlm.nih.gov/pubmed/20711704.
7. Fearon DT, Austen KF (1975) Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med 142: 856-863. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2189935&tool= pmcentrez&rendertype=abstract. Accessed 2012 Jun 7.
8. Zipfel PF, Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9: 729-740. Available: http://www.ncbi.nlm.nih.gov/pubmed/ 19730437. Accessed 2012 Mar 5.
9. Mollnes TE, Song W-C, Lambris JD (2002) Complement in inflammatory tissue damage and disease. Trends Immunol 23: 61-64. Available: http://www.ncbi.nlm. nih.gov/pubmed/11929126.
10. Kemper C, Mitchell LM, Zhang L, Hourcade DE (2008) The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis. Proc Natl Acad Sci U S A 105: 9023-9028. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2449358&tool= pmcentrez&rendertype=abstract.
11. Nolan KF, Reid KB (1993) Properdin. Methods Enzymol 223: 35-46. Available: http://www.ncbi.nlm.nih.gov/pubmed/8271963. Accessed 2013 Nov 14.
12. Schwaeble W, Huemer HP, Möst J, Dierich MP, Ströbel M, et al. (1994) Expression of properdin in human monocytes. Eur J Biochem 219: 759-764. Available: http://www.ncbi.nlm.nih.gov/pubmed/8112326.
13. Robson KJ, Hall JR, Jennings MW, Harris TJ, Marsh K, et al. (1988) A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite. Nature 335: 79-82. Available: http://www.ncbi.nlm.nih.gov/pubmed/3045563. Accessed 2013 Nov 17.
14. Goundis D, Reid KB (1988) Properdin, the terminal complement components, thrombospondin and the circumsporozoite protein of malaria parasites contain similar sequence motifs. Nature 335: 82-85. Available: http://www.ncbi.nlm. nih.gov/pubmed/3045564. Accessed 2013 Nov 29.
15. Pangburn MK (1989) Analysis of the natural polymeric forms of human properdin and their functions in complement activation. J Immunol 142: 202-207. Available: http://www.ncbi.nlm.nih.gov/pubmed/2909614. Accessed 2012 Oct 2.
16. Alcorlo M, Tortajada A, Rodríguez de Córdoba S, Llorca O (2013) Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin. Proc Natl Acad Sci U S A: 1-6. Available: http://www.ncbi.nlm.nih.gov/pubmed/23901101. Accessed 2013 Aug 2.
17. Farries TC, Lachmann PJ, Harrison R a (1988) Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement. Biochem J 253: 667-675. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1149358&tool= pmcentrez&rendertype=abstract.
18. Higgins JMG, Wiedemann H, Timpl R, Reid BM (1995) Characterization of Mutant Forms of Recombinant Human Properdin Lacking Single Thrombospondin Type I Repeats.
19. Daoudaki ME, Becherer JD, Lambris JD (1988) A 34-amino acid peptide of the third component of complement mediates properdin binding. J Immunol 140: 1577-1580. Available: http://www.ncbi.nlm.nih.gov/pubmed/3279119. Accessed 2013 Nov 29.
20. Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, et al. (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308: 421-424. Available: http://www.ncbi.nlm.nih.gov/pubmed/15761121. Accessed 2013 Nov 22.
21. Hageman GS, Anderson DH, Johnson L V, Hancox LS, Taiber AJ, et al. (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102: 7227-7232. Available: http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=1088171&tool=pmcentrez&rendertype=abstract.
22. Fagerness JA, Maller JB, Neale BM, Reynolds RC, Daly MJ, et al. (2009) Variation near complement factor I is associated with risk of advanced AMD. Eur J Hum Genet 17: 100-104. Available: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=2985963&tool=pmcentrez&rendertype=abstract. Accessed 2013 Nov 29.
23. Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, et al. (1998) Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 53: 836-844. Available: http://www.ncbi.nlm.nih.gov/pubmed/9551389. Accessed 2013 Nov 29.
24. Esparza-Gordillo J, Jorge EG de, Garrido CA, Carreras L, López-Trascasa M, et al. (2006) Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 43: 1769-1775. Available: http://www.ncbi.nlm. nih.gov/pubmed/16386793. Accessed 2013 Nov 29.
25. Lesher AM, Nilsson B, Song W-C (2013) Properdin in complement activation and tissue injury. Mol Immunol 56: 191-198. Available: http://www.ncbi.nlm.nih. gov/pubmed/23816404. Accessed 2013 Sep 30.
26. Miwa T, Sato S, Gullipalli D, Nangaku M, Song W-C (2013) Blocking Properdin, the Alternative Pathway, and Anaphylatoxin Receptors Ameliorates Renal Ischemia-Reperfusion Injury in Decay-Accelerating Factor and CD59 Double-Knockout Mice. J Immunol. Available: http://www.ncbi.nlm.nih.gov/pubmed/ 23427256. Accessed 2013 Feb 25.
27. Zhou H-F, Yan H, Stover CM, Fernandez TM, Rodriguez de Cordoba S, et al. (2012) Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm. Proc Natl Acad Sci U S A 109: E415-22. Available: http://www.ncbi.nlm.nih.gov/pubmed/ 22308431. Accessed 2012 Jun 3.
28. Kimura Y, Zhou L, Miwa T, Song W (2010) Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury. J Clin Invest 120: 3545-3554. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=2947218&tool=pmcentrez&rendertype=abstract. Accessed 2013 Jan 6.
29. Dimitrova P, Ivanovska N, Schwaeble W, Gyurkovska V, Stover C (2010) The role of properdin in murine zymosan-induced arthritis. Mol Immunol 47: 1458-1466. Available: http://www.ncbi.nlm.nih.gov/pubmed/20226532. Accessed 2012 Jun 7.
30. Davis P, Cumming RH, Verrier-Jones J (1977) Relationship between anti-DNA antibodies complement consumption and circulating immune complexes in systemic lupus erythematosus. Clin Exp Immunol 28: 226-232. Available: &rendertype=abstract. Accessed 2014 Jan 17.
31. El-Ghobarey A, Whaley K (1980) Alternative pathway complement activation in rheumatoid arthritis. J Rheumatol 7: 453-460. Available: http://www.ncbi.nlm. nih.gov/pubmed/6158571. Accessed 2013 Nov 25.
32. Veszeli N, Füst G, Csuka D, Trauninger A, Bors L, et al. (2013) A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission. Mol Immunol 57: 200-209. Available: http://www.ncbi.nlm.nih.gov/pubmed/24172223. Accessed 2013 Nov 25.
33. Petersen S, Taaning E, Söderström T, Pilgaard B, Tranebjaerg L, et al. (1991) Immunoglobulin and complement studies in children with Schönlein-Henoch Syndrome and other vasculitic diseases. Acta Paediatr Scand 80: 1037-1043. Available: http://www.ncbi.nlm.nih.gov/pubmed/1750337. Accessed 2013 Nov 25.
34. Baatrup G, Jonsson H, Sjöholm A, Sturfelt G, Svehag SE (1988) Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera. J Clin Lab Immunol 26: 73-79. Available: http://www.ncbi.nlm.nih.gov/ pubmed/3264027. Accessed 2013 Nov 20.
35. Ricklin D, Lambris JD (2013) Complement in Immune and Inflammatory Disorders: Therapeutic Interventions. J Immunol 190: 3839-3847. Available: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1203200. Accessed 2013 Apr 6.
36. Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P (2013) Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis 61: 289-299. Available: http://www.ncbi.nlm.nih. gov/pubmed/23141475. Accessed 2013 Dec 2.
37. Gupta-Bansal R, Parent JB, Brunden KR (2000) Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies. Mol Immunol 37: 191-201. Available: http://www.ncbi.nlm.nih.gov/pubmed/10930626.
38. Sjöholm AG, Braconier JH, Söderström C (1982) Properdin deficiency in a family with fulminant meningococcal infections. Clin Exp Immunol 50: 291-297. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=1536695&tool=pmcentrez&rendertype=abstract. Accessed 2013 Nov 15.
39. Pauly D, Kirchner S, Stoermann B, Schreiber T, Kaulfuss S, et al. (2009) Simultaneous quantification of five bacterial and plant toxins from complex matrices using a multiplexed fluorescent magnetic suspension assay. Analyst 134: 2028-2039. Available: http://www.ncbi.nlm.nih.gov/pubmed/19768210. Accessed 2013 Aug 1.
40. Harlow E, Lane D (1988) Using Antibodies: A laboratory manual. Cold Spring Harbor Laboratory Press.
41. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685. Available: http://www.ncbi.nlm.nih.gov/pubmed/5432063. Accessed 2013 Oct 30.
42. Kyhse-Andersen J (1984) Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. J Biochem Biophys Methods 10: 203-209. Available: http://www.ncbi.nlm.nih.gov/pubmed/6530509. Accessed 2013 Oct 31.
43. Thomas A, Klein MS, Stevens AP, Reinders Y, Hellerbrand C, et al. (2013) Changes in the hepatic mitochondrial and membrane proteome in mice fed a non-alcoholic steatohepatitis inducing diet. J Proteomics 80C: 107-122. Available: http://www.ncbi.nlm.nih.gov/pubmed/23313215. Accessed 2013 Nov 26.
44. Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, et al. (1954) The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120: 279-285. Available: http://www.ncbi.nlm.nih.gov/pubmed/13186838. Accessed 2013 Nov 21.
45. Józsi M, Strobel S, Dahse H-M, Liu W, Hoyer PF, et al. (2007) Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 110: 1516-1518. Available: http://www.ncbi.nlm. nih.gov/pubmed/17495132. Accessed 2013 Nov 6.
46. Ish C, Ong GL, Desai N, Mattes MJ (1993) The specificity of alternative complement pathway-mediated lysis of erythrocytes: a survey of complement and target cells from 25 species. Scand J Immunol 38: 113-122. Available: http://www.ncbi.nlm.nih.gov/pubmed/8346410.
47. Retter I, Althaus HH, Münch R, Müller W (2005) VBASE2, an integrative V gene database. Nucleic Acids Res 33: D671-4. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=540042&tool= pmcentrez&rendertype=abstract. Accessed 2013 Aug 19.
48. Leaver-Fay A, Tyka M, Lewis SM, Lange OF, Thompson J, et al. (2011) ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol 487: 545-574. Available: http://www.ncbi.nlm. nih.gov/pubmed/21187238. Accessed 2013 Oct 31.
49. Olimpieri PP, Chailyan A, Tramontano A, Marcatili P (2013) Prediction of site-specific interactions in antibody-antigen complexes: the proABC method and server. Bioinformatics 29: 2285-2291. Available: http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid=3753563&tool=pmcentrez&rendertype=abstract. Accessed 2013 Oct 31.
50. Martin ACR, Allen J (2010) Bioinformatics tools for antibody engineering. In: Duebel S, editor. Handbook of Therapeutic Antibodies. Weinheim, Germany: Wiley-VCH. pp. 95-117.
51. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612. Available: http://www.ncbi.nlm.nih.gov/ pubmed/15264254. Accessed 2013 Oct 31.
52. Rother RP, Rollins S a, Mojcik CF, Brodsky R a, Bell L (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25: 1256-1264. Available: http://www.ncbi.nlm.nih.gov/pubmed/17989688. Accessed 2013 Mar 8.
53. Díaz-Rubio E, Perez EA, Giaccone G (2010) Bevacizumab (Avastin). In: Dübel S, editor. Handbook of Therapeutic Antibodies. Weinheim, Germany: Wiley-VCH. pp. 779-812.
54. Bee C, Abdiche YN, Pons J, Rajpal A (2013) Determining the Binding Affinity of Therapeutic Monoclonal Antibodies towards Their Native Unpurified Antigens in Human Serum. PLoS One 8: e80501. Available: http://www. pubmedcentral.nih.gov/articlerender.fcgi?artid=3819287&tool= pmcentrez&rendertype=abstract. Accessed 2013 Nov 27.
55. Havea P, Singh H, Creamer LK, Campanella OH (1998) Electrophoretic characterization of the protein products formed during heat treatment of whey protein concentrate solutions. J Dairy Res 65: 79-91. Available: http://www.journals.cambridge.org/abstract-S0022029997002641.
56. Karsten CM, Köhl J (2012) The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 217: 1067-1079. Available: http://www.ncbi.nlm.nih.gov/pubmed/22964232. Accessed 2013 Nov 27.
57. Hoffmann LG, Pitts a K, Densen P, Weiler JM, Butler JE, et al. (1987) A sandwich ELISA for properdin in clinical specimens. J Immunol Methods 98: 161-172. Available: http://www.ncbi.nlm.nih.gov/pubmed/3571983.
58. Holers VM (2008) The spectrum of complement alternative pathway-mediated diseases. Immunol Rev 223: 300-316. Available: http://www.ncbi.nlm.nih.gov/ pubmed/18613844.
59. Weber BHF, Issa PC, Pauly D, Herrmann P, Grassmann F, et al. (2014) The role of the complement system in age-related macular degeneration. Dtsch Arztebl Int 111: 133-138. doi:10.3238/arztebl.2014.0133.
60. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8: 643-657. Available: http://www.ncbi.nlm. nih.gov/pubmed/23026949. Accessed 2013 Nov 21.
61. Schmidt CQ, Bai H, Lin Z, Risitano AM, Barlow PN, et al. (2013) Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol 190: 5712-5721. Available: http://www.ncbi.nlm.nih.gov/ pubmed/23616575. Accessed 2013 Dec 2.
62. Fridkis-Hareli M, Storek M, Mazsaroff I, Risitano AM, Lundberg AS, et al. (2011) Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 118: 4705-4713. Available: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=3208285&tool=pmcentrez&rendertype=abstract. Accessed 2013 Dec 2.
63. Kimura Y, Miwa T, Zhou L, Song W-C (2008) Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood 111: 732-740. Available: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=2200840&tool=pmcentrez&rendertype=abstract. Accessed 2012 Apr 25.
64. Heinen S, Pluthero FG, van Eimeren VF, Quaggin SE, Licht C (2012) Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Mol Immunol 54: 84-88. Available: http://www.ncbi.nlm.nih.gov/pubmed/23220071. Accessed 2012 Dec 13.
65. Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, et al. (2005) A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol 42: 87-97. Available: http://www.ncbi.nlm.nih.gov/pubmed/15488947. Accessed 2013 Nov 29.
66. Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith MJ, et al. (1995) Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 96: 1564-1572. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=185782&tool= pmcentrez&rendertype=abstract.
67. Elter T, Engert A, Hallek M (2010) Alemtuzumab (MabCampath). In: Dübel S, editor. Handbook of Therapeutic Antibodies. Weinheim, Germany: Wiley-VCH. pp. 733-777.
68. Kupper H, Salfeld J, Tracey D, Kalden J (2010) Adalimumab (Humira). In: Dübel S, editor. Handbook of Therapeutic Antibodies. Weinheim, Germany: Wiley-VCH. pp. 697-732.
69. Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE (2007) Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol 179: 2600-2608. Available: http://www.ncbi.nlm.nih.gov/pubmed/17675523.
70. Jenne DE, Tschopp J (1989) Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci U S A 86: 7123-7127. Available: http://www. pubmedcentral.nih.gov/articlerender.fcgi?artid=298007&tool= pmcentrez&rendertype=abstract.
71. Schwochau GB, Nath K a, Rosenberg ME (1998) Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int 53: 1647-1653. Available: http://www.ncbi.nlm.nih.gov/pubmed/ 21303217.
72. Johnson L V, Forest DL, Banna CD, Radeke CM, Maloney M a, et al. (2011) Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration. Proc Natl Acad Sci U S A 108: 18277-18282. Available: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=3215058&tool=pmcentrez&rendertype=abstract. Accessed 1 March 2012.
73. Reichert JM (2012) Marketed therapeutic antibodies compendium. MAbs 4: 1-3. Available: http://www.ncbi.nlm.nih.gov/pubmed/22531442. Accessed 2012 Jun 30.
74. Greenaway S, Henniker AJ, Walsh M, Bradstock KF (1994) A pilot clinical trial of two murine monoclonal antibodies fixing human complement in patients with chronic lymphatic leukaemia. Leuk Lymphoma 13: 323-331. Available: http://www.ncbi.nlm.nih.gov/pubmed/8049653. Accessed 2013 Nov 21.
75. Saldanha JW (2010) Molecular Engineering I: Humanization. In: Duebel S, editor. Handbook of Therapeutic Antibodies. Weinheim, Germany: Wiley-Blackwell. pp. 119-144.
76. Mollnes TE, Jokiranta TS, Truedsson L, Nilsson B, Rodriguez de Cordoba S, et al. (2007) Complement analysis in the 21st century. Mol Immunol 44: 3838-3849. Available: http://www.ncbi.nlm.nih.gov/pubmed/17768101. Accessed 2013 Nov 27.
77. Linton SM, Morgan BP (1999) Properdin deficiency and meningococcal disease - identifying those most at risk. Clin Exp Immunol 118: 189-191. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 1905414&tool=pmcentrez&rendertype=abstract.
78. Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, et al. (2013) An international serum standard for application in assays to detect human complement activation products. Mol Immunol 56: 232-239. Available: http://www.ncbi.nlm.nih.gov/pubmed/23787367. Accessed 2013 Nov 8.
79. Somani R, Richardson VR, Standeven KF, Grant PJ, Carter AM (2012) Elevated properdin and enhanced complement activation in first-degree relatives of South Asian subjects with type 2 diabetes. Diabetes Care 35: 894-899. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 3308267&tool=pmcentrez&rendertype=abstract. Accessed 2013 Nov 25.
80. Fredrikson GN, Gullstrand B, Westberg J, Sjöholm a G, Uhlén M, et al. (1998) Expression of properdin in complete and incomplete deficiency: normal in vitro synthesis by monocytes in two cases with properdin deficiency type II due to distinct mutations. J Clin Immunol 18: 272-282. Available: http://www.ncbi.nlm.nih.gov/pubmed/9710744.
81. Scholl HPN, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B, et al. (2008) Systemic complement activation in age-related macular degeneration. PLoS One 3: e2593. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=2440421&tool=pmcentrez&rendertype=abstract. Accessed 2012 Sep 18.
82. Smith a J, Kyle V, Cawston TE, Hazleman BL (1987) Isolation and analysis of immune complexes from sera of patients with polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 46: 468-474. Available: http://www.pubmedcentral. nih.gov/articlerender.fcgi?artid=1002166&tool=pmcentrez&rendertype= abstract.
83. Benbassat C, Schlesinger M, Luderschmidt C, Valentini G, Tirri G, et al. (1993) The complement system and systemic sclerosis. Immunol Res 12: 312-316. Available: http://www.ncbi.nlm.nih.gov/pubmed/8288948.
84. Wolf-Schnurrbusch UEK, Stuck AK, Hess R, Wolf S, Enzmann V (2009) Complement Factor P in choroidal neovascular membranes of patients with age-related macular degeneration. Retina 29: 966-973. Available: http://www.ncbi.nlm.nih.gov/pubmed/19584655. Accessed 2012 Sep 26.